SCHEMBL61836

SCHEMBL61836

COc1cccc(F)c1-c1nc(C)c(COc2cc(C(C)C)ccc2C)c(N2CCN(CC(N)=O)CC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 4/20 0.37
ALDH1A1 P00352 3/20 0.37
TSHR P16473 3/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
ADRA1A P35348 3/20 0.36
HTR1A P08908 1/20 0.36
BCHE P06276 4/20 0.35
ACHE P22303 4/20 0.35
NPSR1 Q6W5P4 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
CCNT1 O60563 1/20 0.34
CDK9 P50750 1/20 0.34
NTRK1 P04629 1/20 0.34
MAP4K1 Q92918 1/20 0.34
LMNA P02545 1/20 0.34
ADRB2 P07550 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63231 0.95 C5AR1 (0.39) C5AR1ALDH1A1TSHRHTTKMT2A
SCHEMBL61189 0.94 C5AR1 (0.40) C5AR1ALDH1A1TSHRHTTKMT2A
SCHEMBL61239 0.91 NR1H4 (0.38) C5AR1ADRA1ABCHEACHEADRB2
SCHEMBL62755 0.91 C5AR1 (0.38) C5AR1ALDH1A1TSHRHTTKMT2A
SCHEMBL61416 0.90 C5AR1 (0.44) C5AR1ALDH1A1HTTBCHEACHE
SCHEMBL63224 0.90 C5AR1 (0.38) C5AR1HTTBCHEACHE
SCHEMBL61097 0.88 C5AR1 (0.39) C5AR1ALDH1A1TSHRHTTKMT2A
SCHEMBL27666453 0.88 CCNT1 (0.42) C5AR1ALDH1A1TSHRKMT2AMEN1
SCHEMBL62473 0.88 CCNT1 (0.42) C5AR1ALDH1A1TSHRKMT2AMEN1
SCHEMBL27666529 0.88 C5AR1 (0.38) C5AR1ALDH1A1TSHRHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482350-B2 4,5-disubstituted-2-aryl pyrimidines NEUROGEN CORPORATION (US) 2009-01-27 US claimed
US-20050277654-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2005-12-15 US claimed
US-8129395-B2 4,5-disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-03-06 US disclosed
US-8129395-B2 4,5-disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-03-06 US disclosed
US-8129395-B2 4,5-disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-03-06 US disclosed
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2010-01-28 US disclosed
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2010-01-28 US disclosed
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2010-01-28 US disclosed
US-7482350-B2 4,5-disubstituted-2-aryl pyrimidines NEUROGEN CORPORATION (US) 2009-01-27 US disclosed
US-7482350-B2 4,5-disubstituted-2-aryl pyrimidines NEUROGEN CORPORATION (US) 2009-01-27 US disclosed
US-7482350-B2 4,5-disubstituted-2-aryl pyrimidines NEUROGEN CORPORATION (US) 2009-01-27 US disclosed
US-20050277654-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277654-A1 4,5-Disubstituted-2-aryl pyrimidines C5AR2, C3AR1, C5AR1 C5AR1 3/4885ALDH1A1 1616/4885TSHR 242/4885
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines C5AR2, C5AR1, C3AR1 C5AR1 2/4885ALDH1A1 1684/4885TSHR 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.